Pacific Biosciences of California, Inc. PACB
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 2.02% | 5.04% | 3.89% | -10.72% | -17.35% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.02% | 5.04% | 3.89% | -10.72% | -17.35% |
| Cost of Revenue | -0.61% | -3.11% | 6.15% | -11.92% | -15.70% |
| Gross Profit | 8.94% | 29.83% | -1.90% | -7.75% | -21.38% |
| SG&A Expenses | -25.40% | -27.80% | -24.40% | -8.86% | -1.63% |
| Depreciation & Amortization | -81.36% | -85.30% | -63.01% | -41.71% | 1.54% |
| Other Operating Expenses | -17.92% | -30.71% | 314.33% | 14.79% | 14.79% |
| Total Operating Expenses | -20.06% | -25.75% | -19.84% | -17.59% | -16.87% |
| Operating Income | 32.81% | 40.97% | 31.39% | 21.38% | 16.59% |
| Income Before Tax | 75.19% | 80.57% | -76.41% | -27.41% | -27.80% |
| Income Tax Expenses | 1,587.76% | 5,642.86% | 0.63% | 160.17% | 100.43% |
| Earnings from Continuing Operations | 75.04% | 80.45% | -76.34% | -27.75% | -31.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 75.04% | 80.45% | -76.34% | -27.75% | -31.46% |
| EBIT | 32.81% | 40.97% | 31.39% | 21.38% | 16.59% |
| EBITDA | -233.43% | -277.89% | 160.10% | 152.20% | 143.25% |
| EPS Basic | 75.90% | 81.33% | -60.91% | -16.29% | -19.63% |
| Normalized Basic EPS | 37.14% | 46.60% | 38.98% | 27.22% | 22.53% |
| EPS Diluted | 75.61% | 81.10% | -61.12% | -16.39% | -19.47% |
| Normalized Diluted EPS | 35.40% | 45.34% | 37.62% | 29.39% | 24.61% |
| Average Basic Shares Outstanding | 5.75% | 7.43% | 9.28% | 9.14% | 8.35% |
| Average Diluted Shares Outstanding | 3.60% | 5.19% | 6.95% | 11.35% | 10.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |